Structural biology of insulin and IGF1 receptors: Implications for drug design

Nature Reviews Drug Discovery

Volumn 1, Issue 10, 2002, Pages 769-783

  De Meyts, Pierre ^a   Whittaker, Jonathan ^a  

^a HAGEDORN RESEARCH INSTITUTE   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR; ERYTHROPOIETIN RECEPTOR; INSULIN; INSULIN DERIVATIVE; INSULIN RECEPTOR; PEPTIDE DERIVATIVE; RECEPTOR ACTIVITY MODIFYING PROTEIN; SEMAXANIB; SOMATOMEDIN C RECEPTOR; TYRPHOSTIN; VASCULOTROPIN INHIBITOR;

BINDING AFFINITY; BLOOD GLUCOSE MONITORING; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; DRUG TARGETING; ELECTRON MICROSCOPY; GENE STRUCTURE; HORMONE ACTION; INSULIN DEFICIENCY; INSULIN TREATMENT; MOLECULAR MECHANICS; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN TARGETING; RAT; REVIEW; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS; X RAY CRYSTALLOGRAPHY; ANIMAL; BINDING SITE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; HUMAN;

ANIMALS; BINDING SITES; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; HUMANS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0036782071     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd917     Document Type: Review

References (152)

1. Amos, A. F., McCarty, D. J. & Zimmet, P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabetic Med. 14 (Suppl. 5), S1-S85 (1997).
2. Bilous, R. W. & Alberti, K. G. M. M. in New Antidiabetic Drugs (eds Bailey, C. J. & Flat, P. R.) 19-32 (Smith-Gordon and Nishimura, London, United Kingdom and Niigata-Shi, Japan, 1990).
3. Yudkin, J. S. Therapeutic targets for type 2 diabetes post-UKPDS. J. R. Coll. Phys. Lond. 34, 254-256 (2000).
4. Standl, E. Insulin analogues - state of the art. Horm. Res. 57 (Suppl. 1), 40-45 (2002).
5. Owens, D. R. New horizons - alternative routes for insulin therapy. Nature Rev. Drug Discov. 1, 529-540 (2002).
6. De Meyts, P. Insulin and insulin-like growth factors: the paradox of signaling specificity. Growth Horm. IGF Res. 12, 81-83 (2002).
7. Adams, T. E., Epa, V. C., Garrett, T. P. & Ward, C. W. Structure and function of the type 1 insulin-like growth factor receptor. Cel. Mol. Life Sci. 57, 1050-1093 (2000)
8. Blume, A. J., Beasley, J. & Goldstein, N. I. The use of peptides in diogenesis: a novel approach to drug discovery and phenomics. Biopolymers 55, 347-356 (2000).
9. Khandwala, H. M., McCutcheon, I. E., Flyvbjerg, A. & Friend, K. E. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endo. Rev. 21, 215-244 (2000).
10. Ebina, Y. et al. The human insulin receptor cDNA: the structural basis for hormone-activated transmembrane signalling. Cell 40, 747-758 (1985).
11. Ullrich, A. et al. Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313, 756-761 (1985).
12. Whittaker, J. et al. High-level expression of human insulin receptor cDNA in mouse NIH 3T3 cells. Proc. Natl Acad. Sci. USA 84, 5237-5241 (1987).
13. Ullrich, A. et al. Insulin-like growth factor-I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity EMBO J. 5, 2503-2512 (1986).
14. Seino, S., Seino, M., Nishi, S. & Bell, G. I. Structure of the human insulin receptor gene and characterization of its promoter. Proc. Natl Acad. Sci. USA 86, 114-118 (1989).
15. Abbott, A. M., Bueno, R., Pedrini, M. T., Murray, J. M. & Smith, R. J. Insulin-like growth factor I receptor gene structure. J. Biol. Chem. 267, 10759-10763 (1992).
16. Hubbard, S. R. & Till, J. H. Protein tyrosine kinase structure and function. Ann. Rev. Biochem. 69, 373-398 (2000).
17. Heldin, C. H. & Ostman, A. Ligand-induced dimerization of growth factor receptors: variations on the theme. Cytokine Growth Factor Rev. 7, 3-10 (1996).
18. Bass, J., Chiu, G., Argon, Y. & Steiner, D. F. Folding of insulin receptor monomers is facilitated by the molecular chaperones calnexin and calreticulin and impaired by rapid dimerization. J. Cell Biol. 141, 637-646 (1998).
19. Seino, S. & Bell, G. I. Alternative splicing of human insulin receptor messenger RNA. Biochem. Biophys. Res. Comm. 159, 312-316 (1989).
20. Soos, M., Field, C. E. & Siddle, K. Purified hybrid insulin/insulin-like growth factor-I receptors bind insulin-like growth factor-I, but not insulin, with high affinity. Biochem. J. 290, 419-426 (1993).
21. Pandini, G. et al. Insulin/IGF1 hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J. Biol. Chem. 2002 Jul 22 (doi: 10.1074/jbc.M202766200).
22. Bajaj, M., Waterfield, M. D., Schlessinger, J., Taylor, W. R. & Blundell, T. L. On the tertiary structure of the extracellular domains of the epidermal growth factor and insulin receptors. Biochim. Biophys. Acta 916, 220-226 (1987).
23. Ward, C. W., Hoyne, P. A. & Flegg, R. H. Insulin and epidermal growth factor receptors contain the cysteine repeat motif found in the tumor necrosis factor receptor. Proteins 22, 141-153 (1995).
24. Marino-Buslje, C., Mizuguchi, K., Siddle, K. & Blundell, T. L. A third fibronectin type III domain in the extracellular region of the insulin receptor family. FEBS Lett. 441, 331-336 (1998).
25. Mulhern, T. D., Booker, G. W. & Cosgrove, L. A third fibronectin-type-III domain in the insulin-family receptors. Trends Biol. Sci. 23, 465-466 (1998).
26. Ward, C. W. Members of the insulin receptor family contain three fibronectin type III domains. Growth Factors 16, 315-322 (1999).
27. Garrett, T. P. et al. Crystal structure of the first three domains of the type-1 insulin-like growth factor receptor. Nature 394, 395-399 (1998).
28. Kristensen, C., Wilberg, F. C., Schäffer, L. & Andersen, A. S. Expression and characterization of a 70-kDa fragment of the insulin receptor that binds insulin. Minimizing ligand binding domain of the insulin receptor. J. Biol. Chem. 273, 17780-17786 (1998).
29. Molina, L., Marino-Buslje, C., Quinn, D. R. & Siddle, K. Structural domains of the insulin receptor and IGF receptor required for dimerisation and ligand binding. FEBS Lett. 467, 226-230 (2000).
30. Hubbard, S. R., Wei, L., Ellis, L. & Hendrickson, W. A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372, 746-754 (1994).
31. Hubbard, S. R. Crystal structure of the activated insulin receptor tyrosine kinase in complex with peptide substrate and ATP analog. EMBO J. 16, 5572-5581 (1997).
32. Favelyukis, S., Till, J. H., Hubbard, S. R. & Miller, W. T. Structure and autoregulation of the insulin-like growth factor 1 receptor kinase. Nature Struct. Biol. 8, 1058-1063 (2001).
33. Pautsch, A. et al. Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into domain movements upon kinase activation. Structure 9, 955-965 (2001).
34. Schaefer, E. M., Erickson, H. P., Federwisch, M., Wollmer, A. & Ellis, L. Structural organization of the human insulin receptor ectodomain. J. Biol. Chem. 267, 23393-23402 (1992).
35. Tulloch, P. A. et al. Single-molecule imaging of human insulin receptor ectodomain and its Fab complexes. J. Struct. Biol. 125, 11-18 (1999).
36. Woldin, C. N., Hing, F. S., Lee, J., Pilch, P. F. & Shipley, G. G. Structural studies of the detergent-solubilized and vesicle-reconstituted insulin receptor. J. Biol. Chem. 274, 34981-34992 (1999).
37. Christiansen, K., Tranum-Jensen, J., Carlsen, J. & Vinten, J. A model for the quaternary structure of human placental insulin receptor deduced from electron microscopy. Proc. Natl Acad. Sci. USA 88, 249-252 (1991).
38. Tranum-Jensen, J., Christiansen, K., Carlsen, J., Brenzel, G. & Vinten, J. Membrane topology of insulin receptors reconstituted into lipid vesicles. J. Membr. Biol. 140, 215-223 (1994).
39. Luo, R. Z., Beniac, D. R., Fernandes, A., Yip, C. C. & Ottensmeyer, F. P. Quaternary structure of the insulin-insulin receptor complex. Science 285, 1077-1080 (1999).
40. Ottensmeyer, F. P., Beniac, D. R., Luo, R. Z. & Yip, C. C. Mechanism of transmembrane signaling: insulin binding and the insulin receptor. Biochemistry 39, 12103-12112 (2000).
41. Slade, A., Luh, J., Ho, S. & Yip, C. M. Single molecule imaging of supported planar lipid bilayer-reconstituted human insulin receptors by in situ scanning probe microscopy. J. Struct. Biol. 137, 283-291 (2002).
42. Saltiel, A. R. New perspectives into the molecular pathogenesis and treatment of type 2 diabetes. Cell 104, 517-529 (2001).
43. Frick, W., Bauer, A., Bauer, J., Wied, S. & Muller, G. Structure-activity relationship of synthetic phosphoinositolglycans mimicking metabolic insulin action. Biochemistry 37, 13421-13436 (1998).
44. Elchebly, M. et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544-1548 (1999).
45. Clement, S. et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409, 92-97 (2001).
46. Zhang, B. et al. Discovery of a small molecule insulin mimetic with antidiabetic activity in mice. Science 284, 974-977 (1999).
47. Air, E. L. et al. Small molecule insulin mimetics reduce food intake and body weight and prevent development of obesity. Nature Med. 8, 179-183 (2002).
48. Manchem, V. P. et al. A novel small molecule that directly sensitizes the insulin receptor in vitro and in vivo. Diabetes 50, 824-830 (2001).
49. Levitzki, A. & Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science 267, 1782-1788 (1995).
50. Mendel, D. B. et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des. 15, 29-41 (2000).
51. Rewcastle, G. W. et al. Tyrosine kinase inhibitors. 14. Structure-activity relationships for methylamino-substituted derivatives of 4-[(3-bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyrimidine (PD 158780). a potent and specific inhibitor of the tyrosine kinase activity of receptors for the EGF family of growth factors. J. Med. Chem. 41, 742-751 (1998).
52. Mohammadi, M. et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain. EMBO J. 17, 5896-5904 (1998).
53. Bilder, G. et al. Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511 A. Circulation 99, 3292-3299 (1999).
54. Parang, K. et al. Mechanism-based design of a protein kinase inhibitor. Nature Struct. Biol. 8, 37-41 (2001).
55. De Meyts, P., Roth, J., Neville, J., Gavin, J. R. & Lesniak, M. A. Insulin interactions with its receptors: experimental evidence for negative cooperativity. Biochem. Biophys. Res. Comm. 55, 154-161 (1973).
56. De Meyts, P., Van Obberghen, E., Roth, J., Brandenburg, D. & Wollmer, A. Mapping of the residues of the receptor binding region of insulin responsible for the negative cooperativity. Nature 273, 504-509 (1978).
57. De Meyts, P. The structural basis of insulin and insulin-like growth factor-I (IGF1) receptor binding and negative cooperativity, and its relevance to mitogenic versus metabolic signaling. Diabetologia 37 (Suppl. 2), S135-S148 (1994).
58. Christoffersen, C. T. et al. Negative cooperativity in the insulin-like growth factor-I (IGF1) receptor and a chimeric IGF1/insulin receptor. Endocrinology 135, 472-475 (1994).
59. Zhang, B. & Roth, R. A. A region of the insulin receptor important for ligand binding (residues 450-601) is recognized by patients autoimmune antibodies and inhibitory monoclonal antibodies. Proc. Natl Acad. Sci. USA 88, 9858-9862 (1991).
60. Kadowaki, H. et al. Mutagenesis of lysine 460 in the human insulin receptor. Effects upon receptor recycling and cooperative interactions among binding sites. J. Biol. Chem. 265, 21285-21296 (1990).
61. Kjeldsen, T. et al. The ligand specificities of the insulin receptor and the insulin-like growth factor-I receptor reside in different regions of a common binding site. Proc. Natl Acad. Sci. USA 88, 4404-4408 (1991).
62. Andersen, A. S. et al. Identification of determinants that confer ligand specificity on the insulin receptor. J. Biol. Chem. 267, 13681-13686 (1992).
63. Schumacher, R., Mosthaf, L., Schlessinger, J., Brandenburg, D. & Ullrich, A. Insulin and insulin-like growth factor-I binding specificity is determined by distinct regions of their cognate receptors. J. Biol. Chem. 266, 19288-19295 (1991).
64. Tavare, J. M. & Siddle, K. Mutational analysis of insulin receptor function: consensus and controversy. Biochim. Biophys. Acta 1178, 21-39 (1993).
65. Hoyne, P. A., Elleman, T. C., Adams, T. E., Richards, K. M. & Ward, C. W. Properties of an insulin receptor with an IGF-1 receptor loop exchange in the cysteine-rich region. FEBS Lett. 469, 57-60 (2000).
66. 2-terminal ligand binding site of the insulin receptor by alanine scanning mutagenesis. J. Biol. Chem 270, 1-5 (1995).
67. De Meyts, P. et al. Identification of a ligand-binding region of the human insulin receptor encoded by the second axon of the gene. Molecular Endocrinology 4, 409-416 (1990).
68. Mynarcik, D. C., Yu, G. Q. & Whittaker, J. Alanine-scanning mutagenesis of a C-terminal ligand binding domain of the insulin receptor α subunit. J. Biol. Chem. 271, 2439-2442 (1996).
69. Mynarcik, D. C., Williams, P. F., Schffer, L., Yu, G. Q. & Whittaker, J. Analog binding properties of insulin receptor mutants. Identification of amino acids interacting with the COOH terminus of the B chain of the insulin molecule. J. Biol. Chem 272, 2077-2081 (1997).
70. Taylor, S. I. et al. Mutations in the insulin receptor gene. Endocr. Rev. 13, 566-595 (1992).
71. Kadowaki, T., Kadowaki, H., Accili, D. & Taylor, S. I. Substitution of lysine for asparagine at position 15 in the α-subunit of the human insulin receptor. A mutation that impairs transport of receptors to the cell surface and decreases the affinity of insulin binding. J. Biol. Chem. 265, 19143-19150 (1990).
72. Rouard, M. et al. Congenital insulin resistance associated with a conformational alteration in a conserved beta-sheet in the insulin receptor L1 domain. J. Biol. Chem. 274, 18487-18491 (1999).
73. Longo, N., Langley, S. D., Griffin, L. D. & Elsas, L. J. Activation of glucose transport by a natural mutation in the human insulin receptor. Proc. Natl Acad. Sci. USA 90, 60-64 (1993).
74. Grønskov, K., Vissing, H., Shymko, R. M., Tornqvist, H. & De Meyts, P. Mutation of arginine 86 to proline in the insulin receptor alpha subunit causes lack of transport of the receptor to the plasma membrane, loss of binding affinity and a constitutively activated tyrosine kinase in transfected cells. Biochem. Biophys. Res. Comm. 192, 905-911 (1993).
75. Nakae, J., Morioka, H., Ohtsuka, E. & Fujieda, K. Replacements of leucine 87 in human insulin receptor alter affinity for insulin. J. Biol. Chem. 270, 22017-22022 (1995).
76. Liu, R. et al. Deletion of lysine 121 creates a temperature-sensitive alteration in insulin binding by the insulin receptor. J. Biol. Chem. 270, 476-482 (1995).
77. Hamer, I. et al. An arginine to cysteine 252 mutation in insulin receptors from a patient with severe insulin resistance inhibits receptor internalisation but preserves signalling events. Diabetologia 45, 657-667 (2002).
78. Roach, P. et al. A novel human insulin receptor gene mutation uniquely inhibits insulin binding without impairing posttranslational processing. Diabetes 43, 1096-1102 (1994).
79. Whittaker, J. & Mynarcik, D. C. Phenotype of the Ser-323 to Leu mutation of the insulin receptor is isoform dependent. Diabetes 47 (Suppl. 1), 264 (1998).
80. Whittaker, J. et al. Alanine scanning mutagenesis of a type 1 insulin-like growth factor receptor ligand binding site. J. Biol. Chem. 276, 43980-43986 (2001).
81. Schäffer, L. A model for insulin binding to the insulin receptor. Eur. J. Biochem. 221, 1127-1132 (1994).
82. Shoelson, S. E., Lee, J., Lynch, C. S., Backer, J. M. & Pilch, P. F. BpaB25 insulins. Photoactivatable analogues that quantitatively crosslink, radiolabel, and activate the insulin receptor. J. Biol. Chem. 268, 4085-4091 (1993).
83. Wang, C. C. et al. Negative and positive site-site interactions, and their modulation by pH, insulin analogs and monoclonal antibodies, are preserved in the purified insulin receptor. Proc. Natl Acad. Sci. USA 85, 8400-8404 (1988).
84. Markussen, J. M., Halstrom, J., Wiberg, F. & Schffer, L. Immobilized insulin for high capacity affinity chromatography of insulin receptors. J. Biol. Chem. 266, 18814-18818 (1991).
85. Yip, C. C. & Jack, E. Insulin receptors are bivalent as demonstrated by photoaffinity labeling. J. Biol. Chem. 267, 13131-13134 (1992).
86. Sweet, L. J., Morrison, B. D. & Pessin, J. Isolation of functional a-b heterodimers from the purified human placental α2-β2 heterotetrameric insulin receptor concept. Structural basis for high affinity ligand binding. J. Biol. Chem. 262, 6939-6942 (1987).
87. Boni-Schnetzler, M., Scott, W., Waugh, S. M., Di Bella, E. & Pilch, P. The insulin receptor. Structural basis for high affinity ligand binding. J. Biol. Chem. 262, 8395-8401 (1987).
88. Bass, J., Kurose, T., Pashmforoush, M. & Steiner, D. F. Fusion of insulin receptor ectodomains to immunoglobulin constant domains reproduces high-affinity insulin binding in vitro. J. Biol. Chem. 271, 19367-19375 (1996).
89. Hoyne, P. A. et al. High affinity insulin binding by soluble insulin receptor extracellular domain fused to a leucine zipper. FEBS Lett. 479, 15-18 (2000).
90. Whittaker, J., Garcia, P., Yu, G. Q. & Mynarcik, D. C. Transmembrane domain interactions are necessary for negative cooperativity of the insulin receptor Mol. Endocrinol. 8, 1521-1527 (1994).
91. Florke, R. R. et al. Hormone-triggered conformational changes within the insulin-receptor ectodomain: requirement for transmembrane anchors. Biochem. J. 360, 189-198 (2001).
92. Baker, E. et al. The structure of 2Zn pig insulin at 1. 5 Å resolution. Phil. Trans. R. Soc. Lond. B 19, 369-456 (1988).
93. Blundell. T. L., Dodson, G. G., Hodgkin, D. C. & Mercola, D. A. Insulin: the structure in the crystal and its reflection in chemistry and biology. Adv. Prot. Chem. 26, 279-402 (1972).
94. Pullen, R. A. et al. Receptor binding region of insulin. Nature 259, 369-373 (1976).
95. Hua, X. H., Shoelson, S. E., Kochoyan, M. & Weiss, M. Receptor binding redefined by a structural switch in a mutant human insulin. Nature 354, 238-241 (1991).
96. Ludvigsen, S., Olsen, H. B. & Kaarsholm, N. C. A structural switch in a mutant insulin exposes key residues for receptor binding. J. Mol. Biol. 279, 1-7 (1998).
97. Kristensen, C. et al. Alanine scanning mutagenesis of insulin. J. Biol. Chem. 272, 12978-12983 (1997).
98. Nakagawa, S. H. & Tager, H. S. Importance of aliphatic side-chain structure at positions 2 and 3 of the insulin A chain in insulin-receptor interactions. Biochemistry 31, 3204-3214 (1992).
99. Nakagawa, S. H., Tager, H. S. & Steiner, D. F. Mutational analysis of invariant valine B12 in insulin: implications for receptor binding. Biochemistry 39, 15826-15835 (2000).
100. van den Brande, J. L. in The Insulin-Like Growth Factors. Structure And Biological Functions (Oxford Univ. Press, Oxford, New York and Tokyo, 1992).
101. Brzozowski, A. M. et al. Structural origins of the functional divergence of human insulin-like growth factor-I and insulin. Biochemistry 41, 9389-9397 (2002).
102. Vajdos, F. F. et al. Crystal structure of human insulin-like growth factor-1: detergent binding inhibits binding protein interactions. Biochemistry 40, 11022-11029 (2001).
103. Bayne, M. L. et al. The C region of human insulin-like growth factor (IGF) I is required for high affinity binding to the type I IGF receptor. J. Biol. Chem. 264, 11004-11008 (1988).
104. Gill, R. et al. Engineering the C-region of human insulin-like growth factor-1: implications for receptor binding. Protein Eng. 9, 1011-1019 (1996).
105. Kristensen, C. et al. A single-chain insulin-like growth factor I/insulin hybrid binds with high affinity to the insulin receptor. Biochem. J. 305, 981-986 (1995).
106. Chen, L. M., Yang, X. W. & Tang, J. G. Acidic residues on the N-terminus of proinsulin C-peptide are important for the folding of insulin precursor. J. Biochem. 131, 855-859 (2002).
107. de Vos, A. M., Ultsch, M. & Kossiakoff, A. A. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306-312 (1992).
108. Raff, M. in Physical Chemical Aspects Of Cell Surface Events In Cellular Regulation (eds DeLisi, C. & Blumenthal, R.) 116 (Elsevier North Holland, New York, Amsterdam, Oxford, 1979).
109. Lee, J., O'Hare, T., Pilch, P. & Shoelson, S. E. Insulin receptor autophosphorylation occurs asymmetrically. J. Biol. Chem. 268, 4092-4098 (1993).
110. Yip, C. C. The insulin-binding domain of the insulin receptor is encoded by exons 2 and 3. J. Cell. Biochem. 48, 19-25 (1992).
111. Hammond, B. J., Tikerpae, J. & Smith, G. D. An evaluation of the crosslinking model for the interaction of insulin with its receptor. Am. J. Physiol. 272, E1136-E1144 (1997).
112. Yeh, J. I. et al. High-resolution structures of the ligand binding domain of the wild-type bacterial aspartate receptor. J. Mol. Biol. 262, 186-201 (1996).
113. Wedekind, F. et al. Hormone binding site of the insulin receptor: an analysis using photoaffinity-mediated avidin complexing. Biol. Chem. 370, 251-258 (1989).
114. Kristensen, C., Andersen, A. S., Ostergaard, S., Hansen, P. H. & Brandt, J. Functional reconstitution of insulin receptor binding site from non-binding receptor fragments. J. Biol. Chem. 277, 18340-18345 (2002).
115. Schumacher, R. et al. Signaling-competent chimeras allow mapping of major insulin receptor binding domains determinants. J. Biol. Chem. 268, 1087-1094 (1993).
116. Fuh, G. et al. Rational design of potent antagonists to the human growth hormone receptor. Science 256, 1677-1680 (1992).
117. Okada, S. & Kopchick, J. J. Biological effects of growth hormone and its antagonist. Trends Mol. Med. 7, 126-132 (2001).
118. Boesen, T. P., Soni, B., Schwartz, T. & Halkier, T. Single-chain vascular endothelial growth factor variant with antagonist activity. J. Biol. Chem. 2002 Jul 31 (doi: 10.1074/jbc.M204107200).
119. Schlein, M. et al. Properties of small molecules affecting insulin receptor function. Biochemistry 40, 13520-13528 (2001).
120. Johnson, D. L. & Jolliffe, L. K. Erythropoietin mimetic peptides and the future. Nephrol. Dial. Transplant. 15, 1274-1277 (2000).
121. Clackson, T. & Wells, J. A. A hot spot of binding energy in a hormone-receptor interface. Science 267, 383-386 (1995).
122. Sidhu, S. S., Lowman, H. B., Cunningham, B. C. & Wells, J. A. Phage display for selection of novel binding peptides. Methods Enzymol. 328, 333-363 (2000).
123. Livnah, O. et al. Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2. 8 Å Science 273, 464-471 (1996).
124. Wrighton, N. C. et al. Increased potency of an erythropoietin peptide mimetic through covalent dimerization. Nature Biotechnol. 15, 1261-1265 (1997).
125. Johnson, D. L. et al. Amino-terminal dimerization of an erythropoietin mimetic peptide results in increased erythropoietic activity. Chem. Biol. 4, 939-950 (1997).
126. Naranda, T. et al. Activation of erythropoietin receptor through a novel extracellular binding site. Endocrinology 143, 2293-2302 (2002).
127. Christopoulos, A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nature Rev. Drug Discov. 1, 198-210 (2002).
128. Qureshi, S. A. et al. Mimicry of erythropoietin by a nonpeptide molecule. Proc. Natl Acad. Sci. USA 96, 12156-12161 (1999).
129. Erlanson, D.A. et al. Site-directed ligand discovery. Proc. Natl Acad. Sci. USA 97, 9367-9372 (2000).
130. Budin, N., Ahmed, S., Majeux, N. & Caflisch, A. An evolutionary approach for structure-based design of natural and non-natural peptidic ligands. Comb. Chem. High Throughput Screen. 4, 661-673 (2001).
131. Fairbrother, W. J. et al. Novel peptides selected to bind vascular endothelial growth factor target the receptor-binding site. Biochemistry 37, 17754-17764 (1998).
132. Pillutla, R. C. et al. Peptides identify the critical hotspots involved in the biological activation of the insulin receptor. J. Biol. Chem. 277, 22590-22594 (2002).
133. Bursavich, M. G. & Rich, D. H. Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. J. Med. Chem. 45, 541-558 (2002).
134. Ward, C. W. & Garrett, T. P. The relationship between the L1 and L2 domains of the insulin and epidermal growth factor receptors and leucine-rich repeat modules. BMC Bioinformatics 2, 4 (2001).
135. Schäffer, L. & Ljungqvist, L. Identification of a disulfide bridge connecting the alpha-subunits of the extracellular domain of the insulin receptor Biochem. Biophys. Res. Comm. 189, 650-653 (1992).
136. Sparrow, L. G. et al. The disulfide bonds in the C-terminal domains of the human insulin receptor ectodomain. J. Biol. Chem. 272, 29460-29467 (1997).
137. Lu, K. & Guidotti, G. Identification of the cysteine residues involved in the class I disulfide bonds of the human insulin receptor: properties of insulin receptor monomers. Mol. Biol. Cell 7, 679-691 (1996).
138. Cheatham, B. & Kahn, C. R. Cysteine 647 in the insulin receptor is required for normal covalent interaction between α- and β-subunits and signal transduction. J. Biol. Chem. 267, 7108-7115 (1992).
139. Yamaguchi, Y. et al. Functional properties of two naturally occuring isoforms of the human insulin receptor in chinese hamster ovary cells. Endocrinology 129, 2058-2066 (1991).
140. Gu, J. L. & De Meyts, P. in Retrospect and Prospect of Protein Research (eds Zai-Ping, L., Zi-Xian, L. & You-Shang, Z.) 120-125 (World Scientific Publishing, Singapore, 1991).
141. McClain, D. A. Different ligand affinities of the two human insulin receptor splice variants are reflected in parallel changes in sensitivity for insulin action. Mol. Endocrinol. 5, 734-739 (1991).
142. Frasca, F. et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol. Cell. Biol. 19, 3278-3288 (1999).
143. Pashmforoush, M., Yoshimasa, Y. & Steiner, D. F. Exon 11 enhances insulin binding affinity and tyrosine kinase activity of the human insulin proreceptor. J. Biol. Chem. 269, 32639-32648 (1994).
144. Marino-Buslje, C., Martin-Martinez, M., Mizuguchi, K., Siddle, K. & Blundell, T. L. The insulin receptor: from protein sequence to structure. Biochem. Soc. Trans. 27, 715-726 (1999).
145. Ward, C. W., Garrett, T. P., McKern, N. M. & Lawrence, L. J. Structure of the insulin receptor family: unexpected relationships with other proteins. Today. Life Sci. 11, 26-32 (1999).
146. Fabry, M. et al. Detection of a new hormone contact site within the insulin receptor ectodomain by the use of a novel photoreactive insulin. J. Biol. Chem. 267, 8950-8956 (1992).
147. Kurose, T. et al. Crosslinking of a B25 azidophenylalanine insulin derivative to the carboxyl-terminal region of the α-subunit of the insulin receptor. J. Biol. Chem. 269, 29190-29197 (1994).
148. Brandt, J., Andersen, A. S. & Kristensen, C. Dimeric fragment of the insulin receptor α-subunit binds insulin with full holoreceptor affinity. J. Biol. Chem. 276, 12378-12384 (2001).
149. Surinya, K. H. et al. Role of insulin receptor dimerization domains in ligand binding, cooperativity, and modulation by anti-receptor antibodies. J. Biol. Chem. 277, 16718-16725 (2002).
150. Waugh, S. M., DiBella, E. E. & Pilch, P. F. Isolation of a proteolitically derived domain of the insulin receptor containing the major site of crosslinking/binding. Biochemistry 28, 3448-3455 (1989).
151. Yip, C. C. et al. Localization of the insulin-binding site to the cysteine-rich region of the insulin receptor α-subunit. Biochem. Biophys. Res. Comm. 157, 321-329 (1988).
152. Cho, H.-S. & Leahy, D. J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297, 1330-1333 (2002).